Optos Announces Full Release of P200MA Device
MARLBOROUGH, MA. – Optos, a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced the full commercial release and installation of its newest device – P200MA – at the prestigious Weill Cornell Medical College, Department of Ophthalmology, New York, NY.
"The P200MA is an amazing device that delivers substantial advancement in retinal disease detection and evaluation for today’s ophthalmologist,” stated Donald D’Amico, MD, Professor and Chairman of Ophthalmology at Weill Cornell Medical College and Ophthalmologist-in-Chief at the New York Presbyterian Hospital. “The optomap® fa color images produce the most eloquent, dramatic, and compelling view of the fundus, which will greatly enhance patient care and education. The device also provides superb image documentation that will be utilized for almost every patient visit.”
Optos’ P200MA device is a new imaging platform that produces the optomap® fa Angiography Procedure. Patients are injected with sodium fluorescein which rapidly works its way through the patient’s blood vessels and enables the doctor to dynamically and rapidly capture ultra-widefield images of the fluoresced blood vessels of the patient’s retina in real time. The device offers advanced image capture and review capabilities in disease diagnosis and treatment monitoring. The optomap® fa Angiography Procedure provides practitioners with access to reimbursement.
“Clinically we expect our new device to be very useful in the diagnosis and management of a number of pole to peripheral pathologies, and particularly diabetes by enabling doctors to carry out highly targeted partial pan-retinal photocoagulation - this will allow for new treatment paradigms and improved patient outcomes,” said Thomas W. Butts, Chief Executive Officer. “We are very pleased to deliver this device to retinal specialists as it opens new global market segments for us within the medical care segment, of which we estimate a target opportunity of approximately 2.7 million procedures annually in our existing markets in North America and Europe.”
Dr. D’Amico and his colleagues at Weill Cornell Eye Associates, a practice group of the Weill Medical College, Department of Ophthalmology, at the New York-Presbyterian Hospital, are using the P200MA to diagnose and treat patients with a myriad of retinal disorders. Weill Cornell Eye Associates is a state-of-the-art facility equipped with advanced diagnostic technologies like the P200MA to help provide high quality patient care. The center offers a full range of ophthalmic services including cataract, cornea and external disease, retinal and vitreous disorders, glaucoma, pediatric ophthalmology, oculoplastics, and neuro-ophthalmology.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.